Drospirenone: The Definitive Guide

What is drospirenone?

Drospirenone is a synthetic progestin, not micronized progesterone and not estrogen. It appears alone in a progestin-only contraceptive and in fixed combinations with different estrogens. Its effect and purpose depend on that complete product. Slynd is contraception; Angeliq combines it with estradiol for menopausal treatment; Yaz combines it with ethinyl estradiol for contraception and specific additional uses. [1], [2], [3], [4]

Drospirenone has anti-mineralocorticoid activity, which can increase blood potassium, and antiandrogenic activity. These mechanisms do not make every preparation a diuretic prescription, a weight-loss medicine or a treatment for menopausal sexual symptoms. “Progesterone-like” also does not mean chemically identical to ovarian progesterone. [1], [2], [4]

This guide checks selected US products and one UK Angeliq SmPC. It distinguishes country-specific amounts and contraindications instead of treating a shared brand name as one universal tablet. A standalone contraceptive label is not an approved instruction for endometrial protection alongside an arbitrary separate estrogen. [1], [2], [3]

Which complete product schedules are verified?

The US Angeliq vasomotor start is the lower drospirenone 0.25 mg/estradiol 0.5 mg pair, with adjustment guided by clinical response. Its vulvar/vaginal-atrophy instruction uses drospirenone 0.5 mg/estradiol 1 mg. Do not copy the UK 2 mg drospirenone amount into that US tablet name. Equally, do not infer that the US lower-strength pair is the UK product. [2], [3]

All checked Angeliq regimens are continuous combinations. There is no added inert-tablet interval merely because a contraceptive blister has one. Slynd’s 4 mg is the active contraceptive amount and its pack includes four inert days; that calendar is not the Angeliq endometrial-protection study. If a clinician proposes separate estrogen with a contraceptive, the off-label protection question needs its own evidence and explicit plan. [1], [2], [3]

Evidence note: named US/UK full labels, with exact indication, route and components kept together. Contraceptive rows are separate comparisons, not approved MHT protocols.

Which benefits belong to which product?

Angeliq treats menopausal estrogen-deficiency symptoms under its country label. Estradiol provides the estrogen component; drospirenone supplies the progestin in the fixed combination. Reducing night sweats can improve sleep if those sweats cause awakenings, but the medicine is not approved to treat every cause of fatigue or low mood. Local vaginal symptoms may need a different product when they are the only treatment goal. [2], [3], [5]

Slynd prevents pregnancy without an estrogen ingredient. A contraceptive trial is not evidence that it replaces missing menopausal estrogen or preserves bone under an MHT indication. Some clinicians use hormonal contraceptives for cycle-related problems, but a user account of symptom improvement does not expand the approved indication or validate standalone endometrial protection with a separate estrogen. [1]

Yaz has specified PMDD and acne indications in eligible people who want oral contraception. Those cannot be assigned to Angeliq or Slynd merely because each contains drospirenone. A mechanism related to androgens or fluid regulation does not prove predictable weight loss, better libido or a mood benefit in every menopausal user. [1], [2], [4]

What should you do about missed tablets?

Use the actual product leaflet. With US Slynd, one missed active tablet is taken as soon as possible and the daily pack continues. If two or more active tablets are missed, take the last missed tablet, continue the pack and use the label’s additional nonhormonal contraception for sex within seven days after the missed tablets. Missed inert tablets are handled differently. Vomiting and diarrhea also have product-specific instructions. [1]

UK Angeliq says take a forgotten tablet as soon as possible, but do not take an extra tablet when more than 24 hours have elapsed; several missed tablets can cause bleeding. The US patient leaflet instead frames the missed dose around whether it is almost time for the next dose. This is a useful reason to retain your country leaflet rather than build one catch-up rule for the ingredient. [2], [3]

Swallow the tablets; a fixed oral combination is not a skin formulation. When changing products, specify whether contraceptive protection is continuing and whether a separate estrogen or progestogen is being stopped. A missed MHT tablet and a missed contraceptive tablet can both matter while having different consequences. [1], [2], [3], [4]

What evidence supports menopausal uterine protection?

Angeliq’s labels describe symptom studies and endometrial findings for complete estradiol-drospirenone combinations. Protection is attached to the studied continuous formulation. It does not establish that a progestin-only contraceptive with inert days will oppose every amount of added estradiol. Likewise, an EE-drospirenone contraceptive efficacy study does not demonstrate a menopause benefit-risk profile. [1], [2], [3], [4]

The systemic MHT labels retain class safety precautions. Major WHI results summarized there concern oral CEE with or without medroxyprogesterone acetate, not a direct Angeliq-versus-patch safety trial. Do not copy those event rates as a precise prediction for drospirenone or claim that anti-mineralocorticoid activity proves fewer heart attacks. Mechanism, surrogate measurements and clinical outcomes are different evidence levels. [2], [3]

The Slynd label specifically says its venous-clot risk with drospirenone alone is unknown, though expected to be lower than an EE-containing drospirenone combination if a risk exists. That is uncertainty, not a guarantee of zero clot risk and not a numerical estimate for Angeliq. [1], [4]

Why do potassium and country-specific contraindications matter?

Drospirenone’s anti-mineralocorticoid activity can increase potassium. US Slynd and Angeliq contraindicate use with renal impairment, hepatic impairment and adrenal insufficiency. Other contraindications depend on the full product, including cancer, unexplained bleeding and estrogen-related vascular restrictions where relevant. A kidney result that seems acceptable under another country’s wording does not change your own label. [1], [2]

The UK Angeliq SmPC differs: it contraindicates severe renal insufficiency or acute renal failure and severe hepatic disease, while discussing supervised use and potassium review in other impairment contexts. This is a real country-label difference, not a reason to self-choose the more permissive wording. The prescriber needs the actual product and jurisdiction. [3]

Review potassium supplements, potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers, regular NSAIDs and other potassium-raising treatment. Strong CYP3A4 inhibitors can increase drospirenone exposure; enzyme inducers may reduce contraceptive efficacy or change bleeding. Do not assume a “gentle” progestin has no interactions. [1], [2], [3], [4]

Breast symptoms, headache, nausea, irregular bleeding and mood changes can occur. New or worsening depression needs prompt advice. Sudden breathlessness, chest pain, a swollen painful leg, weakness, speech or vision changes require urgent assessment. Yaz’s EE-containing contraceptive excludes smokers over age 35 and has its own vascular/migraine restrictions. Its contraindications do not simply transfer to an estrogen-free pill, nor do they vanish because the progestin is the same. [1], [2], [3], [4]

Who needs potassium testing and ordinary follow-up?

Slynd’s US label calls for potassium testing before treatment and during the first treatment cycle in users receiving daily long-term medicines for chronic conditions that can raise potassium. It also advises considering monitoring with long-term strong CYP3A4 inhibitors and reviewing new risk conditions or medicines. This is risk-directed monitoring, not a universal serum-potassium schedule for every user. [1]

The US Angeliq label advises caution with potassium-raising medicines and considering potassium checks during the first month in high-risk users taking strong CYP3A4 inhibitors long-term. UK Angeliq recommends first-month checking in the specified renal/upper-reference-range potassium context, especially with potassium-sparing medicines. Do not collapse these wordings into one identical testing rule. [2], [3]

For menopausal treatment, record both components, continuous use, symptom response, bleeding and adverse effects. NICE recommends an initial three-month review and annual review thereafter, sooner for problems. Persistent unscheduled systemic-HRT bleeding beyond six months after start or three months after change needs prompt assessment, earlier when concerning. Contraception also needs review of missed pills, pregnancy possibility and efficacy-changing interactions. [1], [2], [3], [5]

How should stopping or changing products be planned?

Stopping a contraceptive removes pregnancy prevention. If changing to menopausal treatment, clarify the separate contraception plan first. Stopping Angeliq changes both estradiol and drospirenone together; menopausal symptoms can recur. A switch to separate components needs an explicit protection regimen rather than assuming that an old contraceptive dose fills that role. [1], [2], [3], [4], [5]

NICE allows gradual reduction or immediate cessation of menopausal HRT. That general statement is not a product-specific home taper for every fixed tablet. UK Angeliq says to start the day after completing the previous cyclic/sequential regimen when switching; the new product’s country instructions matter. Suspected serious adverse effects require prompt assessment instead of a routine taper. [2], [3], [5]

Which storage conditions belong to the checked products?

US Slynd says store at 25°C, with excursions permitted from 15–30°C. US Angeliq says 20–25°C, with excursions to 15–30°C. UK Angeliq requires no special storage conditions. These instructions are not interchangeable simply because the brand or progestin name matches. Keep the supplied packaging, expiry and leaflet and ask a pharmacist about heat, damage or uncertain imported products. Permitted excursions are not ideal ongoing storage. [1], [2], [3]

How does it compare with micronized progesterone?

Drospirenone and micronized progesterone are different molecules with different indications and properties. Fixed Angeliq offers one combined daily tablet; separate estradiol/progesterone therapy can allow a different route and individualized continuous or sequential plan under its own evidence. Neither is universally best, and a milligram comparison does not establish potency or equal protection. [2], [3], [5]

The choice should consider uterus status, estrogen route and amount, symptom response, bleeding, mood, kidney/adrenal/liver history, interactions and convenience. Do not assume that antiandrogenic activity guarantees tolerability or that a plant-derived progesterone label supplies a proven breast-risk advantage over every other progestogen. FDA’s first six MHT label approvals do not establish a new Angeliq label or a change in contraceptive warnings. [1], [2], [3], [5], [6]

What do freshly checked contraceptive accounts describe?

The retrieved Slynd page includes perceived benefits in bleeding or cycle-related symptoms and mood, alongside persistent spotting, headaches, anxiety or depression and stopping treatment. Some users wanted an estrogen-free contraceptive. These are mixed personal accounts about that complete contraceptive product, not response rates or evidence that standalone drospirenone protects the endometrium during MHT. [7]

We omit identities, ratings, amounts and individual adjustment timelines. Some comments make their own claims about why acne, weight or mood changed; those mechanisms are not verified by the anecdote. The meaningful follow-up questions are what actually improved, what persisted, whether adverse effects are tolerable and whether the medicine is being used for contraception or a separate menopausal goal. [1], [2], [7]

Common questions about drospirenone

Is drospirenone estrogen?

No. It is a synthetic progestin. Angeliq and Yaz add different estrogen ingredients; Slynd has none. [1], [2], [4] The accompanying estrogen and complete product determine which symptom, contraceptive or protection evidence applies. Do not compare the amount of drospirenone alone and assume the medicines have the same purpose. A standalone contraceptive and a menopausal combination need their own instructions and eligibility review. See the verified product rows. [1], [2], [4]

Does Slynd have an approved MHT indication?

Its checked US indication is contraception. Its label does not approve it as protection for any separate-estrogen regimen. [1] That distinction does not prove a separate estrogen-plus-Slynd plan is always impossible, but the contraceptive label alone does not validate it. Ask the prescriber which source supports every role in the proposed regimen and how protection is ensured. Do not assemble a menopausal schedule from two unrelated labels. See indications and boundaries. [1]

Are US and UK Angeliq the same strength?

No. The selected US pairs contain drospirenone 0.25 or 0.5 mg, whereas the checked UK tablet contains 2 mg with estradiol 1 mg. [2], [3] The estradiol amount and the progestin amount must remain attached to their named components. A familiar brand does not supply one worldwide dose, and tablet counts should not be calculated from the ingredient name alone. Use the actual country label and complete prescription. See the protocol comparison. [2], [3]

Does everyone need potassium blood tests?

The labels direct testing or consideration according to medicines and clinical risk, with different wording by product/country. Do not invent one universal schedule. [1], [2], [3] Clinical risk includes contraindications and interacting medicines, not simply whether a recent result was normal. Tell the clinician about all prescriptions and supplements before asking which testing applies. A label-directed first-cycle or first-month assessment is different from universal indefinite monthly testing. See potassium monitoring. [1], [2], [3]

Is an estrogen-free contraceptive guaranteed clot-free?

No. Slynd’s label explicitly retains uncertainty about drospirenone-alone VTE risk. A combined EE product has different evidence and restrictions. [1], [4] An estrogen-free formulation changes the comparison but does not eliminate every warning, clinical uncertainty or contraindication. Personal clot history and other medical circumstances still matter. A contraceptive review cannot be substituted for evidence about another drospirenone product or menopausal treatment. See the risk distinctions. [1], [4]

Can I copy Yaz’s inert days into Angeliq?

No. The verified Angeliq regimen is continuous; Yaz is a separate contraceptive calendar. [2], [3], [4] An off interval can change exposure to both the estrogen and progestin in a combined menopausal product. The actual pack instructions, missed-tablet rule and follow-up therefore belong together. If a stop or switch is needed, ask for a complete new plan rather than borrow another calendar. See stopping and switching. [2], [3], [4]

Does it guarantee weight loss or better mood?

No. Mechanisms and selected user accounts do not establish predictable personal outcomes. Mood or other adverse effects need review. [1], [2], [7] Anti-mineralocorticoid pharmacology and personal anecdotes do not establish a weight-loss or mood-treatment indication for every preparation. Distinguish the approved purpose from what an individual noticed while other circumstances were changing. Record a troublesome effect and discuss it rather than raising the dose to chase a promised benefit. See public reports and their limits. [1], [2], [7]

Have all its estrogen-containing warnings changed?

No blanket update was verified. Current retrieved product revisions remain identified individually. [2], [4], [6] Confirm the specific approved revision and current package, including the contraceptive or menopausal purpose. A class announcement can describe a regulatory direction without changing every supplied label. Warnings, interactions and contraindications still need product-specific review; altered boxed language is not proof of zero risk. See risks and eligibility. [2], [4], [6]

Glossary

Definitions for interpreting the product, calendar and limitations.

Estrogen

A hormone class that includes estradiol, estrone and estriol.

MHT / HRT

Menopausal hormone therapy; hormone replacement therapy is a broader term.

Vasomotor symptoms

Menopausal hot flashes and night sweats.

GSM

Genitourinary syndrome of menopause: symptoms and tissue changes involving genital and urinary areas.

Systemic treatment

Medicine delivered through the circulation to act throughout the body.

Local treatment

Treatment directed mainly at the tissue where it is applied; some absorption can still occur.

First-pass metabolism

Initial liver processing after a swallowed medicine is absorbed from the gut.

Endometrium

The lining inside the uterus.

Endometrial hyperplasia

Excess growth of uterine lining; some forms can precede cancer.

Progestogen

A medicine class including progesterone and synthetic progestins, used for uterine protection in systemic HRT.

Micronized progesterone

Progesterone processed into small particles to support absorption; route and schedule remain important.

Continuous combined

Estrogen and progestogen taken without planned monthly breaks.

Sequential

Progestogen taken during a defined part of an estrogen-treatment cycle.

Withdrawal bleed

A planned bleed associated with stopping the progestogen part of a sequential regimen.

Hysterectomy

Surgery to remove the uterus; it does not always remove the ovaries.

VTE

Venous thromboembolism: a clot in a vein, including leg clots and pulmonary embolism.

Pulmonary embolism

A clot blocking an artery in the lungs; a medical emergency.

Absolute risk

How often an event occurs in a specified population over a specified time.

Relative risk

An event rate in one group compared with another; it needs baseline risk to show practical size.

Contraindication

A circumstance in which a medicine should not be used according to its label.

Compounded product

A pharmacy-prepared medicine; approval of an ingredient does not approve the finished preparation.

Drospirenone

A synthetic progestin with anti-mineralocorticoid and antiandrogenic activity.

Hyperkalemia

High blood potassium, which can affect heart function.

Anti-mineralocorticoid activity

Effect opposing mineralocorticoid signaling; it can raise potassium.

Progestin-only pill

A contraceptive pill with no estrogen ingredient.

Renal impairment

Reduced kidney function; product labels differ in their restrictions.

Adrenal insufficiency

Inadequate adrenal-hormone production, relevant to potassium risk.

CYP3A4

A metabolic enzyme affected by inducing and inhibiting medicines.

How was this guide researched?

Named full labels define calendars, indications and risks. Marketing records do not prove stock; guidelines inform care without changing authorization. Public accounts remain separate from clinical evidence. Sources identify document revision and access.

How this page was made

This Doserly editorial guide was prepared with AI assistance using public sources checked October 2, 2026. No independent clinician reviewer is claimed. Doserly develops a commercial tracking app. Original figures explain concepts and do not represent trial results. The directory identifies source revisions and access limitations. January 2027 is a review target; new evidence can require an earlier check.

Sources and updates

Related guides